CYP19A1 and breast cancer: Additional mechanistic avenues include inhibition of MDR-associated efflux transporters by sesquiterpene coumarins and aromatase suppression by imidazolyl-substituted coumarins, which are relevant in estrogen-dependent breast cancer.